Abstract: The present invention is directed towards degumming a silk fiber, obtaining high quality silk fibroin solutions and the reconstitution of silk. The invention further relates to a method of accurately and precisely determining mechanical properties of biological fibers such as silk fibers.

Abstract: A method of treating a disease associated with imbalanced or abnormal activity of MMP-7 is diclosed. The method comprises administration of an antibody comprising an antigen recognition region which binds a catalytic site of MMP-7, having complementarity determining region amino acid sequences as set forth in: SEQ ID NOs: 3, 4 and 5 (CDR3), sequentially arranged from N to C on a light chain of the antibody; and SEQ ID NOs: 6, 7 and 8, sequentially arranged from N to C on a heavy chain of the antibody.

Abstract: Described herein are anti-human ATP6VIB2 antibodies. The antibodies can be used to target senescent cells. Thus, the anti-ATP6VIB2 antibodies would be useful in treating diseases and conditions associated with cellular senescence.

Abstract: The invention relates to processes and systems for use in the control of morphology of precipitated silica.

Abstract: Described herein are compounds having Formula I or Formula II: wherein each dashed line independently represents a saturated or unsaturated bond; R1 and R?1 are aryl or heteroaryl as defined herein; and R2 and R?2 are as defined herein. Further described is a method of inhibiting nuclear translocation of ERK1/2 in a cell, by contacting the cell with a compound having Formula I or Formula II. The compounds may also be for use in treating a disease or disorder associated with nuclear translocation of ERK1/2.

Abstract: Disclosed are methods of treating diseases or disorders mediated by dysregulated CDK4/6 and/or Pin 1 activity comprising co-administering a therapeutically effective amount of one or more CDK4/6 inhibitors, and a therapeutically effective amount of one or more Pin1 inhibitors, or a pharmaceutically acceptable salt or salts thereof

Abstract: Using a pre-trained and fixed Vision Transformer (ViT) model as an external semantic prior, a generator is trained given only a single structure/appearance image pair as input. Given two input images, a source structure image and a target appearance image, a new image is generated by the generator in which the structure of the source image is preserved, while the visual appearance of the target image is transferred in a semantically aware manner, so that objects in the structure image are “painted” with the visual appearance of semantically related objects in the appearance image. A self-supervised, pre-trained ViT model, such as a DINO-VIT model, is leveraged as an external semantic prior, allowing for training of the generator only on a single input image pair, without any additional information (e.g., segmentation/correspondences), and without adversarial training. The method may generate high quality results in high resolution (e.g., HD).

Abstract: Formulations (e.g., solutions) comprising one or more water-soluble polymer(s), liposomes, and an aqueous carrier, are provided. The provided solutions are useful for rinsing, and/or immersing therein, a contact lens and/or in the treatment of ocular discomfort, for example, an ocular discomfort associated with a contact lens. Also provided are kits comprising the solution and a contact lens; articles-of-manufacturing comprising the solution and configured for dispending the solution; and methods utilizing the solution.

Abstract: Methods of controlling biological processes by altering the electric field gradient in a test chamber are disclosed. A portion of a surface of the test chamber is attached to at least one immobilized component of the biological process. Microfluidic devices capable of same are also disclosed.

Abstract: Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naïve pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naïve PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naïve PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.

Abstract: Disclosed herein are genetically modified plants having altered biological activity of 3-?-hydroxysteroid dehydrogenase/isomerase (GAME25), or 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plants have an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof. Further disclosed herein are genetically modified plants having altered expression of a gene encoding a 3-?-hydroxysteroid dehydrogenase/isomerase (GAME25), or a 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plant has an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof.

Abstract: The present invention provides humanized monoclonal antibodies that specifically recognize human QSOX1 and inhibit its activity. The humanized antibodies of the present invention were designed following in-silico selection of specific variable region segments, based on their energy scores, and were produced and confirmed to function properly in binding and inhibiting human QSOX1. The present invention further provides pharmaceutical compositions comprising the humanized antibodies and methods for their use in cancer therapy and diagnosis.

Abstract: Provided is a plant exudate, methods for obtaining a plant exudate by inducing the plant to secrete an exudate and systems for the collection of a plant exudate which include: one or more plant container including at least two discrete compartments each configured to accommodate a split root of a plant, the compartments being a root stimulating compartment including one or more input being in fluid communication with at least a source of a plant root stimulant, and a root exudate harvesting compartment, and a root exudate collection compartment in fluid communication with the root exudate harvesting compartment.

Abstract: Provided herein a biodegradable composite comprising a biodegradable polymer and bio-crystals, wherein the bio-crystals are in a concentration of between 1 wt % to 50 wt % of the biodegradable polymer.

Abstract: A system and methods for electron beam imaging or electron beam spectroscopy. The system comprising: a transmission electron microscope (TEM) having a back focal plane; one or more laser-based devices, configured to shift a predetermined portion of an electron wave to an energy that is different from the energy originally provided by the electron source of the TEM; and an electron energy filter that is configured to accept electron waves, at the energy provided by the electron source of the TEM, and further configured to reject electron waves shifted to a different energy by the laser device.

Abstract: Methods of treating a disease or disorder associated with a down or up-regulation of an immune response of a subject are disclosed. The methods comprising administering to the subject a therapeutically effective amount of any one or more of the molecule 1?-2? glycosyl cyclic adenosine diphosphate ribose (1?-2? gcADPR), 1?-3? gcADPR or Tad1 protein.

Abstract: Provided herein a supramolecular assembly comprising a solid porous particle comprising a single-stranded polynucleotide encapsulated by non-covalent organic structure. Specifically, the non-covalent organic structure is melamine-cyanurate, and the single-stranded polynucleotide is ssDNA or ssRNA.

Abstract: A polymeric compound is disclosed herein, having the general formula I: wherein m, n, X, Y, Z and L are as defined herein. Further disclosed herein are lipid bilayers comprising at least one bilayer-forming lipid and the aforementioned polymeric compound, and liposomes comprising such a bilayer, as well as methods, uses and compositions utilizing such bilayers and/or liposomes for reducing a friction coefficient of a surface and/or for inhibiting biofilm formation.

Abstract: Genetically modified phages are provided. Accordingly, there is provided a genetically modified phage comprising a polynucleotide encoding an anti-defense system polypeptide. Also provided are methods of producing and using same.

Abstract: This invention is directed to a method of electrocatalytic reduction of dinitrogen (N2) to ammonia using a poly oxometalate catalyst, an alkali metal cation and a donor of a proton and/or an electron.